Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00203905 · ClinicalTrials.gov registry record · Phase 2
A Study of Chemoradiotherapy for Intermediate Stage/Selected Stage IV Cancers of the Head and Neck
A Phase 2 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00203905 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 23 participants.
The verdict
NCT00203905, a Phase 2 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate time to progression in eligible patients with cancer of the oral cavity, pharynx, larynx, paranasal sinuses, and cervical esophagus when treated with the concomitant chemoradiotherapy regimen of bevacizumab/5-fluorouracil (5-FU)/hydroxyurea/radiation therapy (B-FHX) in comparison to 5-fluorouracil hydroxyurea (FHX) alone.
Interventions
- DRUG 5-Fluorouracil, Hydroxyurea-[FHX], Bevacizumab
- DRUG 5-Fluorouracil, Hydroxyurea-[FHX]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2004-01 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00203905
The ClinicalTrials.gov registry entry for NCT00203905 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 5-Fluorouracil, Hydroxyurea-[FHX], Bevacizumab is the first listed.
NCT00203905 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00203905 about?
NCT00203905 is a clinical study titled "A Study of Chemoradiotherapy for Intermediate Stage/Selected Stage IV Cancers of the Head and Neck". The primary objective of the study is to evaluate time to progression in eligible patients with cancer of the oral cavity, pharynx, larynx, paranasal sinuses, and cervical esophagus when treated with the concomitant chemoradiotherapy regimen of bevacizumab/5-fluorouracil (5-FU)/hydroxyurea/radiation...
What is the current status of trial NCT00203905?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2004-01. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00203905?
The interventions under investigation include: 5-Fluorouracil, Hydroxyurea-[FHX], Bevacizumab (DRUG), 5-Fluorouracil, Hydroxyurea-[FHX] (DRUG).
Who is sponsoring clinical trial NCT00203905?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.